AMEX:XTNT

Stock Analysis Report

Executive Summary

Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally.

Snowflake

Fundamentals

Mediocre balance sheet and overvalued.

Risks

  • Xtant Medical Holdings is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has Xtant Medical Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

11.6%

XTNT

1.1%

US Medical Equipment

-0.6%

US Market


1 Year Return

-35.3%

XTNT

9.9%

US Medical Equipment

0.6%

US Market

XTNT underperformed the Medical Equipment industry which returned 9.5% over the past year.

XTNT underperformed the Market in United States of America which returned 1.1% over the past year.


Share holder returns

XTNTIndustryMarket
7 Day11.6%1.1%-0.6%
30 Day-4.4%0.6%2.2%
90 Day-6.0%2.9%1.1%
1 Year-35.3%-35.3%10.8%9.9%2.9%0.6%
3 Year-79.0%-79.0%70.1%64.9%44.6%35.2%
5 Year-94.9%-94.9%138.9%111.8%61.9%44.2%

Price Volatility Vs. Market

How volatile is Xtant Medical Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

2 weeks ago | Simply Wall St

What Kind Of Share Price Volatility Should You Expect For Xtant Medical Holdings, Inc. (NYSEMKT:XTNT)?

Valuation

Is Xtant Medical Holdings undervalued based on future cash flows and its price relative to the stock market?

30%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Xtant Medical Holdings's share price is below the future cash flow value, and at a moderate discount (> 20%).

Xtant Medical Holdings's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

Xtant Medical Holdings is loss making, we can't compare its value to the US Medical Equipment industry average.

Xtant Medical Holdings is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Xtant Medical Holdings, we can't assess if its growth is good value.


Price Based on Value of Assets

Xtant Medical Holdings has negative assets, we can't compare the value of its assets to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Xtant Medical Holdings expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

64.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Xtant Medical Holdings's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.

Xtant Medical Holdings is not considered high growth as it is expected to be loss making for the next 1-3 years.

Xtant Medical Holdings's revenues are expected to decrease over the next 1-3 years, this is below the United States of America market average.

Unable to compare Xtant Medical Holdings's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Xtant Medical Holdings's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Xtant Medical Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Xtant Medical Holdings performed over the past 5 years?

-45.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Xtant Medical Holdings does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Xtant Medical Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Xtant Medical Holdings's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Xtant Medical Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if Xtant Medical Holdings has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Xtant Medical Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Xtant Medical Holdings's financial position?


Financial Position Analysis

Xtant Medical Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Xtant Medical Holdings's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Xtant Medical Holdings has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if Xtant Medical Holdings's debt level has increased considering it has negative shareholder equity.


Balance Sheet

High level of physical assets or inventory.

Xtant Medical Holdings has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Whilst loss making Xtant Medical Holdings has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.

Whilst loss making Xtant Medical Holdings has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -108.1% per year.


Next Steps

Dividend

What is Xtant Medical Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Xtant Medical Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Xtant Medical Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Xtant Medical Holdings has not reported any payouts.

Unable to verify if Xtant Medical Holdings's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Xtant Medical Holdings has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Xtant Medical Holdings's salary, the management and board of directors tenure and is there insider trading?

1.2yrs

Average management tenure


CEO

Greg Jensen (58yo)

0.5yrs

Tenure

0

Mr. Greg Jensen has been Interim Chief Executive Officer of Xtant Medical Holdings, Inc. since March 18, 2019. Mr. Jensen serves as Vice President of Finance at Xtant Medical Holdings, Inc. since February  ...


Management Age and Tenure

1.2yrs

Average Tenure

58yo

Average Age

The average tenure for the Xtant Medical Holdings management team is less than 2 years, this suggests a new team.


Board Age and Tenure

1.6yrs

Average Tenure

50yo

Average Age

The average tenure for the Xtant Medical Holdings board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Ron Berlin (65yo)

    VP, COO & GM

    • Tenure: 0.7yrs
  • Greg Jensen (58yo)

    VP of Finance

    • Tenure: 0.5yrs
  • Kevin O'Dare

    Vice President of Sales - Eastern US

    • Tenure: 4.8yrs
    • Compensation: US$347.69k
  • Cathy Lundy

    Vice President of Human Resources

    • Tenure: 5yrs
  • Kevin Brandt (53yo)

    Senior VP & Chief Commercial Officer

    • Tenure: 1.2yrs
    • Compensation: US$859.82k
  • Anthony Defalco

    Vice President of Product Development & Operations

    • Tenure: 1.2yrs

Board Members

  • John Bakewell (57yo)

    Director

    • Tenure: 1.6yrs
    • Compensation: US$246.53k
  • Jeffrey Peters (50yo)

    Chairman of the Board

    • Tenure: 1.6yrs
    • Compensation: US$216.32k
  • Bob McNamara (62yo)

    Director

    • Tenure: 1.6yrs
    • Compensation: US$190.14k
  • Matthew Rizzo (47yo)

    Director

    • Tenure: 1.6yrs
    • Compensation: US$43.89k
  • Michael Eggenberg (49yo)

    Director

    • Tenure: 1.6yrs
    • Compensation: US$43.89k

Company Information

Xtant Medical Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Xtant Medical Holdings, Inc.
  • Ticker: XTNT
  • Exchange: AMEX
  • Founded:
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$36.853m
  • Shares outstanding: 13.16m
  • Website: https://www.xtantmedical.com

Number of Employees


Location

  • Xtant Medical Holdings, Inc.
  • 664 Cruiser Lane
  • Belgrade
  • Montana
  • 59714
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XTNTAMEX (NYSE MKT LLC)YesCommon StockUSUSDJul 2010
XMSBST (Boerse-Stuttgart)YesCommon StockDEEURJul 2010

Biography

Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its bi ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/21 00:01
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.